
1. j gastroenterol hepatol. 2007 dec;22(12):2124-9.

living donor liver transplantation hepatitis b cirrhosis.

karasu z(1), akyildiz m, kilic m, zeytunlu m, aydin u, tekin f, yilmaz f, ozacar 
t, akarca u, ersoz g, gunsar f, ilter t, lucey mr.

author information: 
(1)department gastroenterology, ege university medical school, bornova, izmir,
turkey.

background aim: living donor liver transplantation (ldlt) particular
advantages turkey hepatitis b virus (hbv) infection common 
cause cirrhosis, ldlt circumvents difficulties encountered in
the emerging world providing deceased donor organs, allows
preemptive antiviral therapy. aim study review one
institution's experience ldlt patients chronic hbv infection.
methods: total 109 patients chronic hbv infection underwent ldlt
between september 1999 june 2005, 40 coinfected hepatitis d
virus 23 hepatocellular carcinoma. antiviral prophylaxis attempted in
all, beginning prior transplantation lamivudine adefovir, and
continuing transplantation low dose intramuscular hyperimmune b
immunoglobulin (hbig) plus lamivudine adefovir.
results: median follow 20 months (range 1-66 months), no
donor mortality. one-year recipient survival 90%, total 16 recipients 
died. none deaths related hbv. recurrence hbv infection was
detected reappearance serum hepatitis b surface antigen six patients
(5.5%) 5, 8, 12, 17, 34 46 months transplantation, respectively.
there influence donor hepatitis b core antibody status the
likelihood recurrence hbv allograft.
conclusion: results indicate ldlt antiviral treatment low dose 
hbig provides excellent results donors recipients.

doi: 10.1111/j.1440-1746.2006.04782.x 
pmid: 18031369  [indexed medline]

